Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COPD Exacerbation Acute clinical trials
2 of 3 indexed COPD Exacerbation Acute trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
COPD Exacerbation Acute: 3 US clinical trials tracked, 2 recruiting.
COPD Exacerbation Acute is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. The most active sponsor is University of Vermont, running 1 of these trials.
Enrollment posture brief
Registry condition copd-exacerbation-acute
OPEN 2 | RECR 67% | LATE 0 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
COPD Exacerbation Acute lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COPD Exacerbation Acute on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COPD Exacerbation Acute is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
The Reducing REVISITS Study: A Cluster RCT
University of Chicago
NCT05568043
Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia
University of Vermont
NCT05452226
Tolerance and Acute Effects of a New HFNT Nasal Cannula
Temple University
NCT05182294
Phase Distribution
Phase data not available
Top Sponsors
Named interventions
Most-linked intervention names on COPD Exacerbation Acute records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COPD Exacerbation Acute trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COPD Exacerbation Acute page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 COPD Exacerbation Acute trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Vermont sponsors the most COPD Exacerbation Acute trials on record, review their full trial history before evaluating a specific study. See University of Vermont's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COPD Exacerbation Acute condition card totals 3 registered trials; most-linked intervention AIRVO 2, the new asymmetric nasal cannula; top US site state Vermont. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.